| Literature DB >> 17999071 |
Abstract
Idiopathic inflammatory myositides are chronic diseases affecting predominantly the musculoskeletal system and involving high morbidity and mortality. Even when treated with glucocorticosteroids, patients often experience a progressive or relapsing course of the disease, requiring additional immunosuppressants, biologicals, or other therapeutic interventions. Randomized controlled trials on the treatment of primary myositides are still lacking, which means that the optimum therapeutic regimen has still not been defined. This article reviews the current position indicated by the data collected in standard and modern therapeutic options for the treatment of idiopathic inflammatory myositides.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17999071 DOI: 10.1007/s00393-007-0226-9
Source DB: PubMed Journal: Z Rheumatol ISSN: 0340-1855 Impact factor: 1.372